This pharma stock rallies 43% in just 2 days - Do you own? What's fueling it?
Cohance Lifesciences stock rose 19% to Rs 514.60 in the current session against the previous close of Rs 432.70.
- Apr 28, 2026,
- Updated Apr 28, 2026 2:07 PM IST
Shares of Cohance Lifesciences Ltd extended their winning run for the second straight session on Tuesday after the firm appointed the former CEO and Managing Director of Cipla Ltd, Umang Vohra, as Executive Chairman, effective May 1, 2026 and Group CEO, effective May 20, 2026. Vohra succeeds Vivek Sharma, who stepped down as Executive Chairman for personal reasons. Cohance said Sharma would continue to be with the company as an advisor for the next nine months and support a smooth transition.
ALSO READ: How pharma margins are likely to remain under pressure due to US slowdown
Buoyed by the development, the pharma stock zoomed 43% in two sessions. The stock rose 19% to Rs 514.60 in the current session against the previous close of Rs 432.70. Market cap of the firm rose to Rs 18,426 crore.
The appointment of Vohra, said Cohance, reflects a deliberate, strategic decision taken by the board, to bring in a leader whose profile is specifically suited to the demands of the company’s transformation and its next phase of growth.
Umang Vohra said, “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike.
Cohance Lifesciences is a contract development and manufacturing organization (CDMO) that partners with global pharmaceutical and biotechnology companies. It specializes in creating complex molecules, active pharmaceutical ingredients (APIs), specialty chemicals, and formulations. The company's business model is a unified platform built from a series of strategic acquisitions.
Shares of Cohance Lifesciences Ltd extended their winning run for the second straight session on Tuesday after the firm appointed the former CEO and Managing Director of Cipla Ltd, Umang Vohra, as Executive Chairman, effective May 1, 2026 and Group CEO, effective May 20, 2026. Vohra succeeds Vivek Sharma, who stepped down as Executive Chairman for personal reasons. Cohance said Sharma would continue to be with the company as an advisor for the next nine months and support a smooth transition.
ALSO READ: How pharma margins are likely to remain under pressure due to US slowdown
Buoyed by the development, the pharma stock zoomed 43% in two sessions. The stock rose 19% to Rs 514.60 in the current session against the previous close of Rs 432.70. Market cap of the firm rose to Rs 18,426 crore.
The appointment of Vohra, said Cohance, reflects a deliberate, strategic decision taken by the board, to bring in a leader whose profile is specifically suited to the demands of the company’s transformation and its next phase of growth.
Umang Vohra said, “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike.
Cohance Lifesciences is a contract development and manufacturing organization (CDMO) that partners with global pharmaceutical and biotechnology companies. It specializes in creating complex molecules, active pharmaceutical ingredients (APIs), specialty chemicals, and formulations. The company's business model is a unified platform built from a series of strategic acquisitions.